Trial · NCT02246673
Results by group100
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 100
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | Febuxostat 40 mg | -43.5 | Standard Error 1.10 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | Febuxostat 80 mg | -55.6 | Standard Error 1.37 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 10 mg + Febuxostat 40 mg | -70.4 | Standard Error 1.35 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 10 mg + Febuxostat 80 mg | -79.1 | Standard Error 2.53 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 15 mg + Febuxostat 40 mg | -74.9 | Standard Error 1.18 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 15 mg + Febuxostat 80 mg | -82.4 | Standard Error 1.76 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 5 mg + Febuxostat 40 mg | -59.4 | Standard Error 2.81 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 5 mg + Febuxostat 80 mg | -66.7 | Standard Error 2.32 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 2.5 mg + Febuxostat 40 mg | -52.5 | Standard Error 2.51 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 2.5 mg + Febuxostat 80 mg | -62.7 | Standard Error 2.69 | Percentage (%) | |
| Serum Urate Maximum Percentage (%) Change (Emax, CB) | RDEA3170 20 mg + Febuxostat 40 mg | -77.3 | Standard Error 1.18 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | Febuxostat 40 mg | -48.6 | Standard Error 1.71 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | Febuxostat 80 mg | -60.3 | Standard Error 1.58 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 10 mg + Febuxostat 40 mg | -23.7 | Standard Error 5.56 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 10 mg + Febuxostat 80 mg | -36.6 | Standard Error 6.75 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 15 mg + Febuxostat 40 mg | -22.9 | Standard Error 4.15 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 15 mg + Febuxostat 80 mg | -44.4 | Standard Error 5.57 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 5 mg + Febuxostat 40 mg | -26.2 | Standard Error 8.28 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 5 mg + Febuxostat 80 mg | -39.2 | Standard Error 5.95 | Percentage (%) | |
| Urine Uric Acid % Change (0-24h) (Aeur, CB) | RDEA3170 2.5 mg + Febuxostat 40 mg | -40.2 | Standard Error 4.07 | Percentage (%) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02246673/results